Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Apr 27;9(7):101528.
doi: 10.1016/j.adro.2024.101528. eCollection 2024 Jul.

Concurrent Olaparib and Radiation Therapy for BRCA2-Mutated Breast Cancer

Danny Lavigne  1 , Lucas Sideris  2 , Lara de Guerke  3 , Eve-Lyne Marchand  1 , Suzanne Fortin  3 , Pierre Dubé  2 , Peter Vavassis  1 , Marie-Hélène Auclair  3 , Michael Yassa  1
Affiliations
Case Reports

Concurrent Olaparib and Radiation Therapy for BRCA2-Mutated Breast Cancer

Danny Lavigne et al. Adv Radiat Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Eve-Lyne Marchand reports a relationship with AFX Medical that includes consulting or advisory. Peter Vavassis reports a relationship with AbbVie that includes board membership, consulting or advisory, and speaking and lecture fees. Peter Vavassis reports a relationship with Bayer that includes board membership and consulting or advisory. Peter Vavassis reports a relationship with Boston Scientific that includes board membership and consulting or advisory. Peter Vavassis reports a relationship with Knight Therapeutics that includes board membership and consulting or advisory. Peter Vavassis reports a relationship with Novartis that includes board membership and consulting or advisory. Peter Vavassis reports a relationship with Sanofi that includes board membership and consulting or advisory. Peter Vavassis reports a relationship with Sumitomo Pharma that includes board membership and consulting or advisory. Peter Vavassis reports a relationship with TerSera that includes board membership and consulting or advisory. Peter Vavassis reports a relationship with Tolmar that includes board membership, consulting or advisory, and speaking and lecture fees. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Figure 1
Figure 1
Radiation dose distribution on an axial computed tomography slice at the level of the reconstructed breast (A) and dose-volume histogram (B) of the presented patient's radiation therapy plan, the latter representing the volumetric radiation dose received by the breast planning target volume (red curve), axillary and supraclavicular planning target volume (green curve), internal mammary chain planned target volume (orange curve), left lung (cyan curve), spinal cord (blue curve), right lung (purple curve), and heart (pink curve).
Figure 2
Figure 2
The presented patient's cosmetic results 6 weeks after her course of concurrent olaparib and radiation therapy, showing complete resolution of her mild radiodermatitis with no residual treatment sequelae. The temporary blue coloration of her left breast is due to the patent blue dye used for sentinel lymph node biopsy.
See this image and copyright information in PMC

References

    1. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004;95:866–871. - PMC - PubMed
    1. Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: From bench to bedside. Ann Oncol. 2011;22:268–279. - PubMed
    1. Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394–2405. - PMC - PubMed
    1. Geyer CE, Jr., Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250–1268. - PMC - PubMed
    1. Zhu H, Doğan BE. American Joint Committee on Cancer's Staging System for Breast Cancer, eighth edition: Summary for clinicians. Eur J Breast Health. 2021;17:234–238. - PMC - PubMed

Publication types

LinkOut - more resources